Tags

Type your tag names separated by a space and hit enter

Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin.
Gastroenterology. 1981 Mar; 80(3):518-25.G

Abstract

The effects of somatostatin on hepatic and systemic hemodynamics were investigated in 17 patients with chronic liver disease and severe portal hypertension during the hemodynamic assessment before elective portal-systemic shunt surgery. The injection of somatostatin (1.0 microgram/kg) caused a decrease of the wedged hepatic venous pressure, from 19.5 +/- SE 1.3 mmHg to 14.0 +/- 1.0 mmHg (p < 0.001). Injections of 0.5 and 2.0 microgram/kg had similar effects. During somatostatin infusion at a constant rate (7.5 microgram/min) there was a reduction of the wedged hepatic venous pressure (-17.0%, p < 0.001) and estimated hepatic blood flow (-17.5%, p < 0.01) but no significant changes in hepatic vascular resistance, cardiac output, systemic blood pressure, peripheral resistance, or cardiopulmonary pressures. In marked contrast to the selective action of somatostatin on splanchnic hemodynamics, vasopressin infusion (0.3 U/min) in 6 patients caused not only significant falls in the wedged hepatic venous pressure and estimated hepatic blood flow (-28.6% and -31.8%, respectively), but also significant changes in the systemic circulation, including a reduction of the cardiac output (-19.7%, p < 0.01) and heart rate (-12.6%, p < 0.01) and an increase of the arterial pressure (+18.8%, p < 0.01) and peripheral resistance (+46.8%, p < 0.01). These results show that somatostatin effectively reduces hepatic blood flow and portal pressure in patients with cirrhosis and severe portal hypertension, without altering the systemic circulation.

Links

Publisher Full Text

Authors

Bosch J
No affiliation info available
Kravetz D
No affiliation info available
Rodes J
No affiliation info available

MeSH

AdultAgedBlood PressureCardiac OutputFemaleHeart RateHemodynamicsHepatic VeinsHumansHypertension, PortalLiver CirculationLiver CirrhosisMaleMiddle AgedSomatostatinVascular ResistanceVasopressinsVenous Pressure

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

6108897

Citation

Bosch, J, et al. "Effects of Somatostatin On Hepatic and Systemic Hemodynamics in Patients With Cirrhosis of the Liver: Comparison With Vasopressin." Gastroenterology, vol. 80, no. 3, 1981, pp. 518-25.
Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology. 1981;80(3):518-25.
Bosch, J., Kravetz, D., & Rodes, J. (1981). Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology, 80(3), 518-25.
Bosch J, Kravetz D, Rodes J. Effects of Somatostatin On Hepatic and Systemic Hemodynamics in Patients With Cirrhosis of the Liver: Comparison With Vasopressin. Gastroenterology. 1981;80(3):518-25. PubMed PMID: 6108897.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. AU - Bosch,J, AU - Kravetz,D, AU - Rodes,J, PY - 1981/3/1/pubmed PY - 1981/3/1/medline PY - 1981/3/1/entrez SP - 518 EP - 25 JF - Gastroenterology JO - Gastroenterology VL - 80 IS - 3 N2 - The effects of somatostatin on hepatic and systemic hemodynamics were investigated in 17 patients with chronic liver disease and severe portal hypertension during the hemodynamic assessment before elective portal-systemic shunt surgery. The injection of somatostatin (1.0 microgram/kg) caused a decrease of the wedged hepatic venous pressure, from 19.5 +/- SE 1.3 mmHg to 14.0 +/- 1.0 mmHg (p < 0.001). Injections of 0.5 and 2.0 microgram/kg had similar effects. During somatostatin infusion at a constant rate (7.5 microgram/min) there was a reduction of the wedged hepatic venous pressure (-17.0%, p < 0.001) and estimated hepatic blood flow (-17.5%, p < 0.01) but no significant changes in hepatic vascular resistance, cardiac output, systemic blood pressure, peripheral resistance, or cardiopulmonary pressures. In marked contrast to the selective action of somatostatin on splanchnic hemodynamics, vasopressin infusion (0.3 U/min) in 6 patients caused not only significant falls in the wedged hepatic venous pressure and estimated hepatic blood flow (-28.6% and -31.8%, respectively), but also significant changes in the systemic circulation, including a reduction of the cardiac output (-19.7%, p < 0.01) and heart rate (-12.6%, p < 0.01) and an increase of the arterial pressure (+18.8%, p < 0.01) and peripheral resistance (+46.8%, p < 0.01). These results show that somatostatin effectively reduces hepatic blood flow and portal pressure in patients with cirrhosis and severe portal hypertension, without altering the systemic circulation. SN - 0016-5085 UR - https://www.unboundmedicine.com/medline/citation/6108897/Effects_of_somatostatin_on_hepatic_and_systemic_hemodynamics_in_patients_with_cirrhosis_of_the_liver:_comparison_with_vasopressin_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0016508581000498 DB - PRIME DP - Unbound Medicine ER -